Book contents
- Alzheimer’s Disease Drug Development
- Alzheimer’s Disease Drug Development
- Copyright page
- Dedication
- Contents
- Contributors
- Foreword
- Acknowledgments
- Section 1 Advancing Alzheimer’s Disease Therapies in a Collaborative Science Ecosystem
- Section 2 Non-clinical Assessment of Alzheimer’s Disease Candidate Drugs
- Section 3 Alzheimer’s Disease Clinical Trials
- Section 4 Imaging and Biomarker Development in Alzheimer’s Disease Drug Discovery
- 32 Development of Fluid Biomarkers for Alzheimer’s Disease
- 33 Brain Imaging for Alzheimer’s Disease Clinical Trials
- 34 Sharing of Alzheimer’s Disease Research Data in the Global Alzheimer’s Association Interactive Network
- 35 Pharmacogenetics in Alzheimer’s Disease Drug Discovery and Personalized Treatment
- 36 The Role of Electroencephalography in Alzheimer’s Disease Drug Development
- Section 5 Academic Drug-Development Programs
- Section 6 Public–Private Partnerships in Alzheimer’s Disease Drug Development
- Section 7 Funding and Financing Alzheimer’s Disease Drug Development
- Index
- References
35 - Pharmacogenetics in Alzheimer’s Disease Drug Discovery and Personalized Treatment
from Section 4 - Imaging and Biomarker Development in Alzheimer’s Disease Drug Discovery
Published online by Cambridge University Press: 03 March 2022
Book contents
- Alzheimer’s Disease Drug Development
- Alzheimer’s Disease Drug Development
- Copyright page
- Dedication
- Contents
- Contributors
- Foreword
- Acknowledgments
- Section 1 Advancing Alzheimer’s Disease Therapies in a Collaborative Science Ecosystem
- Section 2 Non-clinical Assessment of Alzheimer’s Disease Candidate Drugs
- Section 3 Alzheimer’s Disease Clinical Trials
- Section 4 Imaging and Biomarker Development in Alzheimer’s Disease Drug Discovery
- 32 Development of Fluid Biomarkers for Alzheimer’s Disease
- 33 Brain Imaging for Alzheimer’s Disease Clinical Trials
- 34 Sharing of Alzheimer’s Disease Research Data in the Global Alzheimer’s Association Interactive Network
- 35 Pharmacogenetics in Alzheimer’s Disease Drug Discovery and Personalized Treatment
- 36 The Role of Electroencephalography in Alzheimer’s Disease Drug Development
- Section 5 Academic Drug-Development Programs
- Section 6 Public–Private Partnerships in Alzheimer’s Disease Drug Development
- Section 7 Funding and Financing Alzheimer’s Disease Drug Development
- Index
- References
Summary
Alzheimer’s disease (AD) is a priority health problem devoid of curative treatment. The medication currently available includes acetylcholinesterase inhibitors (AChEIs)(donepezil, rivastigmine, galantamine, huperzine) and memantine. Only one new drug has been approved by the FDA in the last 17 years, so a shift in the paradigm of finding new treatments seems imperative. This involves a better understanding of AD pathogenesis, identifying predictive biomarkers, and customizing treatments. The implementation of pharmacogenomic procedures is an efficient option to optimize the scarce resources available and to accelerate the discovery of new treatments. The pharmacogenomic machinery is composed of pathogenic, mechanistic, metabolic, transporter and pleiotropic genes, under strict regulatory control of epigenetic mechanisms. Since dementia patients suffer from other concomitant diseases and receive up to 10 or more different medications, pharmacogenetics predicts therapeutic response, reduce drug interactions, and limit the adverse effects of anti-dementia drugs.
Keywords
- Type
- Chapter
- Information
- Alzheimer's Disease Drug DevelopmentResearch and Development Ecosystem, pp. 404 - 417Publisher: Cambridge University PressPrint publication year: 2022
References
Cacabelos, R, Fernández-Novoa, L, Lombardi, V, et al. Molecular genetics of Alzheimer’s disease and aging. Meth Find Exp Clin Pharmacol 2005; 27 : 1–573.Google ScholarPubMed
Cacabelos, R. Have there been improvement in Alzheimer’s disease drug discovery over the past 5 years? Expert Opin Drug Discov 2018; 13: 523–38.CrossRefGoogle ScholarPubMed
Cacabelos, R, Cacabelos, N, Carril, JC. The role of pharmacogenomics in adverse drug reactions. Expert Rev Clin Pharmacol 2019; 12 : 407–42.CrossRefGoogle ScholarPubMed
Cacabelos, R, Cacabelos, P, Torrellas, C, et al. Pharmacogenomics of Alzheimer’s disease: novel therapeutic strategies for drug development. Methods Mol Biol 2014; 1175 : 323–556.Google Scholar
Cacabelos, R, Carril, JC, Cacabelos, P, et al. Pharmacogenomics of Alzheimer’s disease: genetic determinants of phenotypic variation and therapeutic outcome. J Genomic Med Pharmacogenomics 2016; 1 : 151–209.Google Scholar
Cacabelos, R, Carril, JC, Sanmartín, A, et al. Pharmacoepigenetic processors: epigenetic drugs, drug resistance, toxicoepigenetics, and nutriepigenetics. In Pharmacoepigenetics, Cacabelos, R (ed.). San Diego, CA: Academic Press/Elsevier; 2019: 191–424.Google Scholar
Kozyra, M, Ingelman-Sundberg, M, Lauschke, VM. Rare genetic variants in cellular transporters, metabolic enzymes, and nuclear receptors can be important determinants of interindividual differences in drug response. Genet Med 2017; 19 : 20–9.Google Scholar
Zhou, ZW, Chen, XW, Sneed, KB, et al. Clinical association between pharmacogenomics and adverse drug reactions. Drugs 2015; 75 : 589–631.CrossRefGoogle ScholarPubMed
Cacabelos, R, Tellado, I, Cacabelos, P. The epigenetic machinery in the life cycle and pharmacoepigenetics. In Pharmacoepigenetics, Cacabelos, R (ed.). San Diego, CA: Academic Press/Elsevier; 2019: 1–100.Google Scholar
Cacabelos, R. Pleiotropy and promiscuity in pharmacogenomics for the treatment of Alzheimer’s disease and related risk factors. Future Neurol 2018; 13.Google Scholar
Cacabelos, R. Epigenomic networking in drug development: from pathogenic mechanisms to pharmacogenomics. Drug Dev Res 2014; 75 :348–65.Google Scholar
Dorszewska, J, Prendecki, M, Oczkowska, A, et al. Molecular basis of familial and sporadic Alzheimer’s disease. Curr Alzheimer Res 2016; 13 : 952–63.Google Scholar
Jamal, S, Goyal, S, Shanker, A, et al. Computational screening and exploration of disease-associated genes in Alzheimer’s disease. J Cell Biochem 2017; 118 : 1471–9.Google Scholar
Zhou, L, Li, HY, Wang, JH, et al. Correlation of gene polymorphisms of CD36 and ApoE with susceptibility of Alzheimer disease: a case–control study. Medicine (Baltimore) 2018; 97: e12470.Google Scholar
Davies, G, Harris, SE, Reynolds, CA, et al. A genome-wide association study implicates the APOE locus in nonpathological cognitive ageing. Mol Psychiatry 2014; 19 : 76–87.Google Scholar
Cacabelos, R. Pharmacogenetic considerations when prescribing cholinesterase inhibitors for the treatment of Alzheimer’s disease. Expert Opin Drug Metab Toxicol 2020; 16: 673–701.Google Scholar
Shapira, M, Tur-Kaspa, I, Bosgraaf, L, et al. A transcription-activating polymorphism in the ACHE promoter associated with acute sensitivity to anti-acetylcholinesterases. Hum Mol Genet 2000; 9 : 1273–81.Google Scholar
Lane, R, Feldman, HH, Meyer, J, et al. Synergistic effect of apolipoprotein E epsilon4 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer’s disease. Pharmacogenet Genomics 2008; 18 : 289–98.Google Scholar
Cuddy, LK, Seah, C, Pasternak, SH, et al. Amino-terminal β-amyloid antibody blocks β-amyloid-mediated inhibition of the high-affinity choline transporter CHT. Front Mol Neurosci 2017; 10: 361.Google Scholar
Payette, DJ, Xie, J, Guo, Q. Reduction in CHT1-mediated choline uptake in primary neurons from presenilin-1 M146V mutant knock-in mice. Brain Res 2007; 1135 : 12–21.Google Scholar
Wang, Y, Zhou, Z, Tan, H, et al. Nitrosylation of vesicular transporters in brain of amyloid precursor protein/presenilin 1 double transgenic mice. J Alzheimers Dis 2017; 55 :1683–92.Google Scholar
Nagy, PM, Aubert, I. Overexpression of the vesicular acetylcholine transporter increased acetylcholine release in the hippocampus. Neuroscience 2012; 218 : 1–11.CrossRefGoogle ScholarPubMed
Kolisnyk, B, Al-Onaizi, MA, Xu, J, et al. Cholinergic regulation of hnRNPA2/B1 translation by M1 muscarinic receptors. J Neurosci 2016; 36 : 6287–96.Google Scholar
Dolejší, E, Liraz, O, Rudajev, V, et al. Apolipoprotein E4 reduces evoked hippocampal acetylcholine release in adult mice. J Neurochem 2016; 136 :503–9.Google Scholar
Albin, RL, Bohnen, NI, Muller, MLTM, et al. Regional vesicular acetylcholine transporter distribution in human brain: A [18F]fluoroethoxybenzovesamicol positron emission tomography study. J Comp Neurol 2018; 526 : 2884–97.Google Scholar
Wallace, TL, Bertrand, D. Importance of the nicotinic acetylcholine receptor system in the prefrontal cortex. Biochem Pharmacol 2013; 85 : 1713–20.Google Scholar
Ma, KG, Qian, YH. Alpha 7 nicotinic acetylcholine receptor and its effects on Alzheimer’s disease. Neuropeptides 2019; 73 : 96–106.CrossRefGoogle ScholarPubMed
Sadigh-Eteghad, S, Talebi, M, Mahmoudi, J, et al. Selective activation of α7 nicotinic acetylcholine receptor by PHA-543613 improves Aβ25–35-mediated cognitive deficits in mice. Neuroscience 2015; 298 : 81–93.Google Scholar
Li, L, Liu, Z, Jiang, YY, et al. Acetylcholine suppresses microglial inflammatory response via α7nAChR to protect hippocampal neurons. J Integr Neurosci 2019; 18 : 51–6.Google ScholarPubMed
McKeever, PM, Kim, T, Hesketh, AR, et al. Cholinergic neuron gene expression differences captured by translational profiling in a mouse model of Alzheimer’s disease. Neurobiol Aging 2017; 57 : 104–19.Google Scholar
Vauthier, V, Housset, C, Falguières, T. Targeted pharmacotherapies for defective ABC transporters. Biochem Pharmacol 2017; 136 :1–11.CrossRefGoogle ScholarPubMed
Cacabelos, R, Llovo, R, Fraile, C, et al. Pharmacogenetic aspects of therapy with cholinesterase inhibitors: the role of CYP2D6 in Alzheimer’s disease pharmacogenetics. Curr Alzheimer Res 2007; 4 : 479–500.Google Scholar
Cacabelos, R. Donepezil in Alzheimer’s disease: from conventional trials to pharmacogenetics. Neuropsychiatr Dis Treat 2007; 3 : 303–33.Google Scholar
Brewster, JT, Dell’Acqua, S, Thach, DQ, et al. Classics in chemical neuroscience: donepezil. ACS Chem Neurosci 2019; 10 : 155–67.Google Scholar
Noetzli, M, Eap, CB. Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer’s disease. Clin Pharmacokinet 2013; 52 : 225–41.Google Scholar
Noetzli, M, Guidi, M, Ebbing, K, et al. Population pharmacokinetic approach to evaluate the effect of CYP2D6, CYP3A, ABCB1, POR and NR1I2 genotypes on donepezil clearance. Br J Clin Pharmacol 2014; 78 : 135–44.CrossRefGoogle ScholarPubMed
Cacabelos, R. World Guide for Drug Use and Pharmacogenomics. Corunna: EuroEspes Publishing; 2012.Google Scholar
Xiao, T, Jiao, B, Zhang, W, et al. Effect of the CYP2D6 and APOE polymorphisms on the efficacy of donepezil in patients with Alzheimer’s disease: a systematic review and meta-analysis. CNS Drugs 2016; 30 : 899–907.CrossRefGoogle ScholarPubMed
Cacabelos, R, Martínez, R, Fernández-Novoa, L, et al. Genomics of dementia: APOE- and CYP2D6-related pharmacogenetics. Int J Alzheimers Dis 2012; 2012: 518901.Google Scholar
Zhong, Y, Zheng, X, Miao, Y, et al. Effect of CYP2D6*10 and APOE polymorphisms on the efficacy of donepezil in patients with Alzheimer’s disease. Am J Med Sci 2013; 345 : 222–6.Google Scholar
Yaowaluk, T, Senanarong, V, Limwongse, C, et al. Influence of CYP2D6, CYP3A5, ABCB1, APOE polymorphisms and nongenetic factors on donepezil treatment in patients with Alzheimer’s disease and vascular dementia. Pharmgenomics Pers Med 2019; 12 : 209–24.Google Scholar
Sokolow, S, Li, X, Chen, L, et al. Deleterious effect of butyrylcholinesterase K-variant in donepezil treatment of mild cognitive impairment. J Alzheimers Dis 2017; 56 : 229–37.Google Scholar
Russo, P, Kisialiou, A, Moroni, R, et al. Effect of genetic polymorphisms (SNPs) in CHRNA7 gene on response to acetylcholinesterase inhibitors (AChEI) in patients with Alzheimer’s disease. Curr Drug Targets 2017; 18 : 1179–90.Google Scholar
Noetzli, M, Guidi, M, Ebbing, K, et al. Relationship of CYP2D6, CYP3A, POR, and ABCB1 genotypes with galantamine plasma concentrations. Ther Drug Monit 2013; 35 : 270–5.Google Scholar
Birks, JS, Grimley Evans, J. Rivastigmine for Alzheimer’s disease. Cochrane Database Syst Rev 2015; 10: CD001191.Google Scholar
Gul, A, Bakht, J, Mehmood, F. Huperzine-A response to cognitive impairment and task switching deficits in patients with Alzheimer’s disease. J Chin Med Assoc 2019; 82 : 40–3.Google Scholar
Lin, PP, Li, XN, Yuan, F, et al. Evaluation of the in vitro and in vivo metabolic pathway and cytochrome P450 inhibition/induction profile of huperzine A. Biochem Biophys Res Commun 2016; 480 : 248–53.Google Scholar
Noetzli, M, Guidi, M, Ebbing, K, et al. Population pharmacokinetic study of memantine: effects of clinical and genetic factors. Clin Pharmacokinet 2013; 52 : 211–23.Google Scholar
Cacabelos, R, Goldgaber, D, Vostrov, A, et al. APOE-TOMM40 in the pharmacogenomics of dementia. J Pharmacogenomics Pharmacoproteomics 2014; 5: 135.Google Scholar
Cacabelos, R, Carril, JC, Cacabelos, N, et al. Sirtuins in Alzheimer’s disease: SIRT2-related genophenotypes and implications for pharmacoepigenetics. Int J Mol Sci 2019; 20: E1249.CrossRefGoogle ScholarPubMed